INmune Bio, Inc.
XPro1595
Alzheimer's disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews XPro1595 for Alzheimer's disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“the registrational strategy is also supported by the favorable safety profile observed in the Phase 2 MINDFuL trial, including no observed ARIA-E or ARIA-H, an important differentiating feature for a disease-modifying Alzheimer’s program fo”